Fredun Pharmaceuticals
1,796.60
+148.60(+9.02%)
Market Cap₹964.04 Cr
PE Ratio24.61
IndustryHealthcare
Company Performance:
1D+9.02%
1M+16.94%
6M+60.56%
1Y+144.20%
5Y+257.92%
View Company Insightsright
More news about Fredun Pharmaceuticals
08Nov 25
Fredun Pharmaceuticals Reports 128% Surge in Q2 Profit, Revenue Up 45%
Fredun Pharmaceuticals Limited announced impressive Q2 FY2026 results with net profit soaring 128% to ₹9.73 crore from ₹4.27 crore year-on-year. Revenue from operations grew 45% to ₹149.59 crore, while EPS doubled to ₹20.61. The half-year net profit reached ₹16.50 crore, up from ₹8.40 crore in the previous period. The Board approved these unaudited results on November 8, 2025, after a meeting lasting over six hours. The company's trading window was closed from October 1, 2025, until 48 hours post-results declaration, adhering to SEBI regulations. Statutory auditors R.H. Nisar & Co. conducted a limited review, finding no material misstatements.
 no imag found
09Oct 25
Fredun Pharmaceuticals Enters Pet Care Market with Strategic Acquisition of Wagr.ai
Fredun Pharmaceuticals Limited (FPL) has acquired Wagr.ai, a pet tech platform, marking its entry into India's pet care sector. The zero-cash transaction gives FPL a 78% stake via a subsidiary. FPL plans to relaunch Wagr.ai as a neutral online marketplace for pet products and services in Q4 FY 2025-26. The acquisition combines FPL's pet nutrition expertise with Wagr's technology, offering telemedicine services, a pan-India doctor network, and AI-powered pet care support. FPL aims to reintroduce Wagr's patented pet fitness tracking technology in FY 2026-27. India's pet care market is projected to reach $6 billion by 2030, with a 22% CAGR from 2021 to 2030.
 no imag found
05Sept 25
Fredun Pharmaceuticals Appoints Daisy Cyril Dsouza as Additional Independent Director
Fredun Pharmaceuticals Limited has appointed Ms. Daisy Cyril Dsouza as an Additional Independent Director for a five-year term from November 24, 2023 to November 23, 2028. Ms. Dsouza, with a Master's in Commerce from the University of Mumbai, brings extensive banking experience from Mandvi Bank and Saraswat Bank. She is not related to any existing company personnel and is not debarred from holding directorial positions.
 no imag found
31Jul 25
Fredun Pharmaceuticals Reports 64% Jump in Net Profit for Q1, Appoints New Directors
Fredun Pharmaceuticals Limited reported strong Q1 results with a 64% year-over-year increase in net profit to ₹6.77 crore. Total income rose by 52% to ₹119.86 crore, while EBITDA grew 62% to ₹16.99 crore. The company maintains a robust order book exceeding ₹200 crore and received a credit rating upgrade to IVR BBB/Stable. Additionally, Fredun appointed two new independent directors, Mr. Anshu Agarwal and Ms. Sonal Desai, to its board for five-year terms.
 no imag found
30Jul 25
Fredun Pharmaceuticals Approves Q1 Results, Appoints Two Independent Directors
Fredun Pharmaceuticals' board approved Q1 FY2025-26 unaudited financial results and appointed two new Independent Directors, Mr. Anshu Agarwal and Ms. Sonal Desai, for five-year terms. The company closed its trading window for insiders and scheduled an Earnings Conference Call for August 1, 2025, to discuss the Q1 results.
 no imag found
10Jul 25
Fredun Pharma Receives SEBI Adjudication Order: No Financial Penalty Imposed
Fredun Pharmaceuticals Limited has received an adjudication order from SEBI addressing several alleged regulatory violations. The order, dated June 30, 2025, cites issues including non-compliance with Indian Accounting Standards, improper audit report submissions, and corporate governance lapses. Despite the violations, SEBI has not imposed any financial penalty on the company. Fredun Pharma states that the order has no impact on its financial or operational activities.
 no imag found
30Jun 25
Fredun Pharmaceuticals Expands into Pet Care with One Pet Stop Acquisition
Fredun Pharmaceuticals has acquired One Pet Stop, marking its entry into the pet care industry. This strategic move aims to diversify the company's business portfolio beyond its traditional pharmaceutical market. The acquisition could potentially allow Fredun to leverage its pharmaceutical expertise in developing specialized pet health products, tapping into the growing pet care market driven by increasing pet ownership trends and demand for premium pet products.
 no imag found
11Apr 25
Fredun Pharma Secures Major Tender from Tamil Nadu Medical Services Corporation
Fredun Pharma has secured a significant tender from the Tamil Nadu Medical Services Corporation (TNMSC) for supplying generic medicines. The contract, valued between Rs. 150.00 crore and Rs. 180.00 crore, is expected to boost the company's revenue, enhance its market position, and demonstrate its capability in meeting government tender requirements. This achievement marks Fredun Pharma's expansion in the government healthcare supply chain and could lead to increased production scale and potential opportunities in other states.
 no imag found
09Apr 25
Fredun Pharma Secures Rs. 150-180 Crore Tender from Tamil Nadu Medical Services Corporation
Fredun Pharmaceuticals Limited has been awarded a tender by the Tamil Nadu Medical Services Corporation (TNMSC) for supplying generic medicines. The tender, valued between Rs. 150-180 crore, will be executed over 14 months starting from Q1 FY26. The medicines will be supplied under the company's 'Fredun Gx' brand. This development is expected to significantly boost Fredun Pharma's revenue and strengthen its position in the public health sector.
 no imag found
18Mar 25
Fredun Pharma's Freossi Division Makes International Debut in Sri Lanka
Fredun Pharmaceuticals Limited's pet care division, Freossi, has launched nine premium pet care products in Sri Lanka, marking its first international expansion. The product range includes MCHC, functional, therapeutic, and grooming lines. Over 20 additional products are under review by Sri Lankan regulators. The launch event was inaugurated by Prof. Ashoka Dangolla and received positive feedback from industry experts. Managing Director Fredun Medhora expressed enthusiasm about the expansion and its potential impact on pet welfare in Sri Lanka.
 no imag found
12Mar 25
Fredun Pharmaceuticals Expands Veterinary Portfolio with Large Animal Healthcare Products
Fredun Pharmaceuticals Limited has announced its entry into the large animal healthcare segment with the launch of two new products under the FREOSSI Large Animals brand. The company introduced Freossi Tone+, a lactation solution for large animals, and Freossi Power, focused on strength and mobility for livestock. Both products are formulated with Microcrystalline Hydroxyapatite Complex (MCHC) and other scientifically backed ingredients. This strategic expansion builds on the company's success in companion animal care and aims to strengthen its position in the animal health industry. The move is part of a broader strategy to expand Fredun Pharma's footprint in veterinary healthcare.
 no imag found
11Mar 25
Fredun Pharmaceuticals Expands Veterinary Portfolio with Large Animal Products
Fredun Pharmaceuticals Limited has announced its entry into the large animal products segment, expanding its veterinary healthcare business. The company is launching two new products under the FREOSSI Large Animals brand: Freossi Tone+, a lactation solution, and Freossi Power, a supplement for strength and mobility in livestock. Freossi Tone+ aims to improve milk yield, quality, and lactation cycles in large animals, while Freossi Power targets joint issues and mobility in horses, bulls, ponies, and cattle. This strategic move diversifies Fredun Pharma's product portfolio and strengthens its presence in the animal health sector.
 no imag found
Fredun Pharmaceuticals
1,796.60
+148.60
(+9.02%)
1 Year Returns:+144.20%
Industry Peers
Sun Pharmaceutical
1,704.60
(+0.56%)
Divis Laboratories
6,113.50
(+1.48%)
Torrent Pharmaceuticals
3,997.20
(+1.48%)
Cipla
1,342.50
(+0.94%)
Dr Reddys Laboratories
1,275.50
(+2.76%)
Lupin
2,196.80
(+1.06%)
Zydus Life Science
923.45
(+3.97%)
Mankind Pharma
2,081.90
(+1.05%)
Aurobindo Pharma
1,203.70
(+1.07%)
Alkem Laboratories
5,750.50
(+1.17%)